GENEROUS Signings Jump From Seven to 40 States in a Week
Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.
Forty states signed. Reporting last week put it at seven. The list CMS has never published is the manufacturers.
Thirty-six fewer items produced the same saving. Nothing about efficacy changed. The medicines that grew paid for it.
Coverage will call this a mental health guideline. One recommendation reaches into a commercial market and tells its providers to turn business away.
Seven of 19 applicant states have signed. CMS itself tells them to check whether its international price beats the rebates they already have.
An industry association found the public agrees with industry. The news came later, from a division director naming headcount as the bottleneck.
The expansion is the announcement. Payers covering 165 million pledged to align with a model none of their members can join.
Coverage is calling these new AI rules. What they propose is replacing the single approval decision with supervised entry and permanent monitoring.
This is a device listing, not an eligibility expansion. The indication is unchanged, and the criteria were relaxed back in April 2025.
Four words carry the news: follows a reconsideration. CDA-AMC reached a different conclusion first, and neither release says what it was.
The useful information is who is absent. The mid-sized biotech coalition formed to contest MFN has no member among the nine signatories.